Weekly Shot Of New Drug Hailed As Functional Cure For Hep B
Scientists found that bepirovirsen prevents the virus from replicating in patients with chronic hepatitis B infections, allowing the immune system to attack. An FDA decision about whether GlaxoSmithKline may market the drug in the U.S. is expected in late October, The New York Times reported.